<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139227</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-17006</org_study_id>
    <secondary_id>NCI-2017-00517</secondary_id>
    <nct_id>NCT03139227</nct_id>
  </id_info>
  <brief_title>Apigenin in Increasing Health Benefits in High Risk Breast Clinic Patients</brief_title>
  <official_title>Celery-Based Dietary Intervention: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the side effects and best dose of apigenin in increasing
      health benefits in high risk breast clinic patients. Celery is high in apigenin, a compound
      that may have anti-cancer activities. Eating a celery-based diet may help in prevention and
      treatment of inflammatory diseases including cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES; I. To determine the feasibility of apigenin oral supplementation using a
      specially formulated celery-banana bread.

      II. To determine the safety and tolerability of apigenin supplementation.

      OUTLINE: This is a dose-escalation study.

      Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7,
      and then consume one serving of higher dose apigenin celery-banana bread on days 8-14.
      Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion,
      on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients
      also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI decision
  </why_stopped>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Actual">March 14, 2019</completion_date>
  <primary_completion_date type="Actual">March 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apigenin levels in blood and urine</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Paired t-tests will be used to compare mean apigenin levels.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Health Status Unknown</condition>
  <arm_group>
    <arm_group_label>Supportive Care (celery-banana bread)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bio specimen Collection</intervention_name>
    <description>Patients undergo collection of blood and urine</description>
    <arm_group_label>Supportive Care (celery-banana bread)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Intervention</intervention_name>
    <description>Consume celery-banana bread</description>
    <arm_group_label>Supportive Care (celery-banana bread)</arm_group_label>
    <other_name>Dietary Modification</other_name>
    <other_name>intervention, dietary</other_name>
    <other_name>Nutrition Intervention</other_name>
    <other_name>Nutrition Interventions</other_name>
    <other_name>Nutritional Interventions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Supportive Care (celery-banana bread)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients should be followed in Stefanie Spielman Comprehensive Breast Center (SSCBC)
             High Risk Breast Clinic

          -  No known allergy to ingredients of banana bread preparation (eggs, almonds and other
             nuts since the celery also has almond powder)

          -  Must be &gt; 1 year from pregnancy, lactation or chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Ability to give informed consent

          -  Participate in the specified study visits and laboratory testing including three (20
             mL) blood draws and three 24 hour urine collections

        Exclusion Criteria:

          -  Concurrent malignancy or metastatic malignancy of any kind

          -  Ongoing chemotherapy, radiation therapy, or other cancer-related treatment

          -  Current and past history of hypertension

          -  Chronic use of any herbal or dietary supplement containing apigenin within the 3
             months prior to entry on the study

          -  Pregnant or nursing women

          -  Concurrent use of tamoxifen, raloxifene, or any of the aromatase inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sagar Sardesai, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

